School of Acupuncture-Moxibustion, Tuina and Rehabilitation, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Medicine (Baltimore). 2024 Feb 23;103(8):e37324. doi: 10.1097/MD.0000000000037324.
This study aimed to evaluate the efficacy and safety of electroacupuncture (EA) in the treatment of benign prostatic hyperplasia.
Seven databases were searched from the inception of each database to March 31, 2023, including PubMed, Web of Science, Cochrane, Embase, China National Knowledge Infrastructure, Wanfang, and China Biology Medicine. The modified Jadad scale was used to assess literature quality, and literature inclusion and exclusion were conducted in strict accordance with the criteria of a score of ≥4. The risk of bias was evaluated using the Cochrane risk of bias tool. The pooled effect size of the binary data was measured by odds ratio (OR) and 95% confidence interval (CI), and the pooled effect size of the continuous data was presented as weighted mean difference (WMD) and 95% CI. If I² was larger than 50%, a random effects model was adopted, and otherwise, a fixed effects model was used. Additionally, publication bias assessment and sensitivity analysis were conducted.
A total of 325 records were retrieved, and finally 9 randomized controlled trial studies were included, involving 1045 patients. Meta-analysis revealed that the EA group had better improvement than the control group in terms of clinical effective rate (odds ratio = 3.92, 95% CI = 2.38 to 6.47, I² = 0%, P < .001), International Prostate Symptom Score (WMD = -4.99, 95% CI = -6.15 to -3.84, I² = 76.9%, P < .001), maximum urinary flow rate (WMD = -4.99, 95% CI = -6.15 to -3.84, I² = 87.4%, P < .001), and post-void residual volume (WMD = -17.12, 95% CI = -29.49 to -4.75, I² = 89.1%, P < .01). There was no statistical significance in prostate volume and adverse events between the EA group and the control group (P > .05).
EA is effective in the treatment of benign prostatic hyperplasia with acceptable overall safety.
本研究旨在评估电针（EA）治疗良性前列腺增生的疗效和安全性。
从每个数据库的创建到 2023 年 3 月 31 日，检索了 7 个数据库，包括 PubMed、Web of Science、Cochrane、Embase、中国知网、万方和中国生物医学文献数据库。使用改良 Jadad 量表评估文献质量，并严格按照评分≥4 分的标准进行文献纳入和排除。使用 Cochrane 偏倚风险工具评估偏倚风险。二分类数据的合并效应量采用比值比（OR）和 95%置信区间（CI）表示，连续性数据的合并效应量采用加权均数差（WMD）和 95%CI 表示。如果 I²大于 50%，采用随机效应模型，否则采用固定效应模型。此外，还进行了发表偏倚评估和敏感性分析。
共检索到 325 条记录，最终纳入 9 项随机对照试验研究，共 1045 例患者。Meta 分析结果显示，EA 组在临床有效率（OR=3.92，95%CI=2.38 至 6.47，I²=0%，P<.001）、国际前列腺症状评分（WMD=-4.99，95%CI=-6.15 至-3.84，I²=76.9%，P<.001）、最大尿流率（WMD=-4.99，95%CI=-6.15 至-3.84，I²=87.4%，P<.001）和剩余尿量（WMD=-17.12，95%CI=-29.49 至-4.75，I²=89.1%，P<.01）方面均优于对照组。EA 组和对照组在前列腺体积和不良反应方面差异无统计学意义（P>.05）。
EA 治疗良性前列腺增生有效，总体安全性可接受。
